# 2026年2月23日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 利用表观遗传调节克服胰腺癌免疫抑制的研究进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41723543)
**期刊：** Clinical epigenetics
**PMID：** 41723543
**DOI：** 10.1186/s13148-026-02081-5

### 第一部分 原文与翻译

**英文原标题：** Epigenetic modulation to overcome immune suppression in pancreatic cancer.

> **英文摘要：**
> Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, primarily due to its highly fibrotic and immunosuppressive tumor microenvironment (TME), which limits both drug delivery and immune cell infiltration. Epigenetic dysregulation plays a pivotal role in shaping these barriers by controlling transcriptional programs that govern tumor-immune interactions, stromal remodeling, and immune evasion.This review synthesizes current insights into the contribution of aberrant epigenetic mechanisms to PDAC progression and immune resistance. We outline how epigenetic alterations suppress antigen presentation, sustain immunosuppressive cell populations, such as regulatory T cells, myeloid-derived suppressor cells, and tumor-associated macrophages, and upregulate immune checkpoint molecules across cancer and stromal compartments. Emerging evidence shows that epigenetic therapies targeting DNA methyltransferases, histone deacetylases, histone methyltransferases, or bromodomain proteins can restore tumor immunogenicity, reprogram cancer-associated fibroblasts, and promote cytotoxic T cell infiltration. Furthermore, combining epigenetic modulators with immune checkpoint blockade or targeted therapies has demonstrated the capacity to remodel the PDAC TME and convert immunologically 'cold' tumors into more responsive ones. Therefore, we also summarize key completed and ongoing clinical trials in PDAC and solid tumors, emphasizing outcomes and biomarker discoveries that support the translation of epigenetic-immunotherapy combinations into clinical practice. Finally, we discuss persistent challenges that impede progress, including poor drug penetration through the desmoplastic stroma, off-target effects and toxicity of epigenetic agents, tumor hypoxia, adaptive resistance, and the scarcity of physiologically relevant immuno-oncology models.Findings from preclinical and early clinical studies indicate that epigenetic reprogramming represents a promising avenue to overcome PDAC immunoresistance by reactivating antigen presentation, disrupting immunosuppressive cellular networks, and enhancing antitumor immunity. However, realizing this potential will require rationally designed combination regimens, predictive biomarkers for patient stratification, and a deeper understanding of cell type-specific and context-dependent epigenetic regulation. Only through these advances can the integration of epigenetic modulation with immunotherapy and stroma-targeting approaches ultimately redefine therapeutic strategies for patients with PDAC.

> **中文摘要：**
> 胰腺导管腺癌（PDAC）仍然是最致命的恶性肿瘤之一，主要归因于其高度纤维化和免疫抑制的肿瘤微环境（TME），这限制了药物递送和免疫细胞浸润。表观遗传失调通过控制驱动肿瘤-免疫相互作用、间质重塑和免疫逃逸的转录程序，在形成这些障碍中发挥着关键作用。本综述综合了关于异常表观遗传机制对 PDAC 进展和免疫耐药贡献的最新见解。我们概述了表观遗传改变如何抑制抗原提呈，维持免疫抑制细胞群体（如调节性 T 细胞、髓源性抑制细胞和肿瘤相关巨噬细胞），并上调癌症及间质组分中的免疫检查点分子。新兴证据表明，针对 DNA 甲基转移酶、组蛋白去乙酰化酶、组蛋白甲基转移酶或溴结构域蛋白的表观遗传疗法可以恢复肿瘤免疫原性，重编程癌症相关成纤维细胞，并促进细胞毒性 T 细胞浸润。此外，将表观遗传调节剂与免疫检查点阻断或靶向疗法相结合，已显示出重塑 PDAC TME 并将免疫“冷”肿瘤转变为更具反应性肿瘤的能力。因此，我们还总结了 PDAC 和实体瘤中已完成和正在进行的关键临床试验，强调了支持将表观遗传-免疫联合疗法转化为临床实践的结果和生物标志物发现。最后，我们讨论了阻碍进展的持续挑战，包括通过促结缔组织增生间质的药物渗透性差、表观遗传药物的脱靶效应和毒性、肿瘤缺氧、适应性耐药以及缺乏生理相关的免疫肿瘤学模型。临床前和早期临床研究结果表明，通过重新激活抗原提呈、破坏免疫抑制细胞网络并增强抗肿瘤免疫，表观遗传重编程代表了克服 PDAC 免疫耐药的一条有前景的途径。然而，实现这一潜力需要合理设计的联合方案、用于患者分层的预测性生物标志物，以及对细胞类型特异性和背景依赖性表观遗传调节的更深入理解。只有通过这些进展，表观遗传调节与免疫疗法及间质靶向方法的整合才能最终重新定义 PDAC 患者的治疗策略。

### 第二部分 AI 大师评价

本文深入探讨了表观遗传调控在破解胰腺癌（PDAC）免疫抑制微环境中的核心价值。综述系统总结了表观遗传失调如何通过多机制构建免疫屏障，并重点评估了DNA/组蛋白修饰酶抑制剂在重塑TME及增强免疫应答中的创新应用。文章不仅梳理了从机制到临床试验的转化路径，还客观分析了药物渗透和毒性等瓶颈问题，为PDAC的表观遗传-免疫联合治疗提供了具有前瞻性的学术指导。

---

## 2. 异基因造血干细胞移植治疗主要T细胞淋巴瘤亚型：欧洲血液与骨髓移植学会（EBMT）淋巴瘤工作组的一项分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41723532)
**期刊：** Journal of hematology & oncology
**PMID：** 41723532
**DOI：** 10.1186/s13045-026-01783-w

### 第一部分 原文与翻译

**英文原标题：** Allogeneic stem cell transplantation for major T-cell lymphoma entities: an analysis of the EBMT-lymphoma working party.

> **英文摘要：**
> BACKGROUND: Allogeneic hematopoietic stem cell transplantation (allo-SCT) is an established treatment for peripheral T-cell lymphoma (PTCL), particularly for patients with relapsed/refractory (r/r) disease. We aimed to retrieve novel information on the role of histology, disease status prior to transplantation, and donor choice for patients with PTCL not otherwise specified (NOS), angioimmunoblastic T-cell lymphoma (AITL), and anaplastic lymphoma kinase (ALK)-negative ALCL. We compared imaging by computed tomography (CT) or positron emission tomography (PET) for defining disease status prior to allo-SCT. METHODS: Eligible were adult patients with PTCL-NOS, AITL, and ALK-negative ALCL undergoing allo-SCT between 2010 and 2022 and reported to EBMT. RESULTS: 1958 patients underwent allo-SCT. Of patients with known number of prior lines of therapies (n = 1310), 301 (23%), 431 (32.9%) and 578 (44.1%) patients received allo-SCT after one (1L), two (2L) or three or more therapy lines (3L +), respective. Three-year GvHD-free, relapse-free survival (GRFS), progression-free survival (PFS) and overall survival (OS) were 35.8%, 50.9% and 56.8%, respectively. Three-year relapse incidence (RI) and non-relapse mortality were 25.1% and 24.1%, respectively. In multivariate analysis, histology other than AITL, no complete response (CR) at transplantation, having a haploidentical donor and higher age at allo-SCT resulted in significantly lower PFS and/or OS. Prior autologous SCT had no impact on the results of allo-SCT and major outcomes did not significantly change when the analyses were restricted to the patients with PET-based response at allo-SCT. Patients allografted in partial response (PR) or SD/PD still achieved long-term survival with a 3-year PFS/OS of 46%/53.7% and 39.6%/43.6%, respectively. CONCLUSION: Allo-SCT is a valid treatment option in relapsed/refractory PTCL where targeted therapies still play a limited role. Patients with AITL survived significantly better than patients with PTCL NOS or ALK-negative ALCL following a significantly lower RI, also when comparing CR/complete metabolic response (CMR) and PR patients separately. Higher age and non-CR at allo-SCT are associated with worse outcomes.

> **中文摘要：**
> 背景：异基因造血干细胞移植（allo-SCT）是外周T细胞淋巴瘤（PTCL）的一种成熟治疗手段，特别是针对复发/难治性（r/r）疾病患者。本研究旨在获取关于组织学、移植前疾病状态以及供体选择对非特指型外周T细胞淋巴瘤（PTCL-NOS）、血管免疫母细胞性T细胞淋巴瘤（AITL）和间变性淋巴瘤激酶（ALK）阴性间变性大细胞淋巴瘤（ALCL）患者作用的新信息。我们比较了计算机断层扫描（CT）或正电子发射断层扫描（PET）成像在定义allo-SCT前疾病状态方面的价值。方法：研究对象为2010年至2022年间在EBMT登记并接受allo-SCT的成年PTCL-NOS、AITL和ALK阴性ALCL患者。结果：共有1958名患者接受了allo-SCT。在已知既往治疗线数的患者（n = 1310）中，分别有301例（23%）、431例（32.9%）和578例（44.1%）患者在经过一线（1L）、二线（2L）或三线及以上（3L+）治疗后接受了allo-SCT。三年无移植物抗宿主病且无复发生存率（GRFS）、无进展生存率（PFS）和总生存率（OS）分别为35.8%、50.9%和56.8%。三年复发率（RI）和非复发死亡率分别为25.1%和24.1%。多变量分析显示，非AITL组织学、移植时未达到完全缓解（CR）、使用单倍体相合供体以及移植时年龄较大与PFS和/或OS显著降低相关。既往自体移植（SCT）对allo-SCT的结果没有影响，且当分析局限于移植时基于PET评估反应的患者时，主要临床结局未发生显著变化。处于部分缓解（PR）或疾病稳定/进展（SD/PD）状态下接受异基因移植的患者仍实现了长期生存，其3年PFS/OS分别为46%/53.7%和39.6%/43.6%。结论：在靶向治疗作用仍有限的复发/难治性PTCL中，allo-SCT是一种有效的治疗选择。AITL患者在移植后的生存状况显著优于PTCL-NOS或ALK阴性ALCL患者，这归因于其复发率显著降低，且在分别比较CR/完全代谢缓解（CMR）和PR患者时结果一致。高龄和移植时未达CR与较差的预后相关。

### 第二部分 AI 大师评价

该研究利用EBMT大规模真实世界数据，系统评估了异基因造血干细胞移植（allo-SCT）在多种T细胞淋巴瘤亚型中的疗效。研究明确了AITL亚型具有更优的移植预后，并揭示了高龄、非CR状态和单倍体供体是生存受限的风险因子。其核心贡献在于证实了即便处于非CR状态的挽救性移植仍能使部分患者获得长期生存，为复发难治性PTCL的个体化移植决策提供了关键的循证医学证据，具有极高的临床指导价值。

---

## 3. DNA甲基化介导的HNF1B沉默促进膀胱癌进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41723508)
**期刊：** Clinical epigenetics
**PMID：** 41723508
**DOI：** 10.1186/s13148-026-02079-z

### 第一部分 原文与翻译

**英文原标题：** DNA methylation-mediated silencing of HNF1B promotes bladder cancer progression.

> **英文摘要：**
> BACKGROUND: Hepatocyte nuclear factor 1 homeobox B (HNF1B), a developmentally crucial transcription factor, demonstrates tumor-suppressive functions in several cancers, with epigenetic silencing being a known mechanism, as seen in malignancies like ovarian and prostate carcinoma. Its functional significance in bladder cancer pathogenesis is far less clear. RESULTS: Our analysis of clinical cohorts identified low HNF1B expression as an independent prognostic factor that is significantly associated with adverse clinicopathological characteristics and poorer survival in bladder cancer patients. Functionally, knockdown of HNF1B promoted bladder cancer cell proliferation, migration, and invasion, whereas its overexpression suppressed these malignant phenotypes in vitro and attenuated tumor growth in vivo. Mechanistically, HNF1B silencing was primarily mediated by promoter hypermethylation. Furthermore, we demonstrated that HNF1B exerts its tumor-suppressive roles by concurrently inhibiting the mitogen-activated protein kinase (MAPK) signaling pathway and the epithelial-mesenchymal transition (EMT) process. CONCLUSION: Our study unveils a novel epigenetic mechanism in bladder cancer, whereby promoter hypermethylation silences HNF1B, thereby promoting tumor progression through activation of the MAPK pathway. These findings establishe HNF1B status as a potential biomarker for stratifying patients who may benefit from targeted therapies against this pathway.

> **中文摘要：**
> 背景：肝细胞核因子1同源框B（HNF1B）是一种在发育中起关键作用的转录因子，在多种癌症中表现出抑癌功能，其表观遗传沉默是已知的发病机制，如在卵巢癌和前列腺癌等恶性肿瘤中所见。然而，其在膀胱癌发病机制中的功能意义尚不明确。结果：我们对临床队列的分析发现，低HNF1B表达是膀胱癌患者的一个独立预后因素，与不良的临床病理特征和较差的生存率显著相关。在功能上，敲低HNF1B可促进膀胱癌细胞的增殖、迁移和侵袭，而其过表达则在体外抑制了这些恶性表型，并在体内减弱了肿瘤生长。机制上，HNF1B的沉默主要由启动子高甲基化介导。此外，我们证明了HNF1B通过同时抑制丝裂原活化蛋白激酶（MAPK）信号通路和上皮-间质转化（EMT）过程来发挥其抑癌作用。结论：本研究揭示了膀胱癌中一种新型的表观遗传机制，即启动子高甲基化导致HNF1B沉默，进而通过激活MAPK通路促进肿瘤进展。这些发现确立了HNF1B状态可作为一种潜在的生物标志物，用于对可能从针对该通路的靶向治疗中获益的患者进行分层。

### 第二部分 AI 大师评价

本研究通过临床队列分析、分子生物学实验及动物模型，系统性地阐明了HNF1B在膀胱癌中的抑癌作用及其表观遗传调控机制。研究重点揭示了启动子高甲基化引起的HNF1B失活是驱动膀胱癌恶性进展的关键因素，并明确了其下调MAPK通路和抑制EMT的核心分子路径。该发现不仅丰富了膀胱癌的表观遗传学理论，还为患者的精准预后分层及MAPK通路的靶向干预提供了重要的生物标志物依据，具有较强的临床转化价值。

---

## 4. Hedgehog信号通路驱动胃肠胰神经内分泌肿瘤中的神经胶质细胞可塑性与致癌重编程

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41723447)
**期刊：** Molecular cancer
**PMID：** 41723447
**DOI：** 10.1186/s12943-026-02611-y

### 第一部分 原文与翻译

**英文原标题：** Hedgehog signaling drives glial cell plasticity and oncogenic reprogramming in gastroenteropancreatic neuroendocrine neoplasms.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

该研究深入探讨了Hedgehog信号通路在胃肠胰神经内分泌肿瘤（GEP-NENs）中的致病机制，重点阐述了其驱动神经胶质细胞可塑性和致癌重编程的核心作用。研究结果揭示了肿瘤微环境中神经胶质细胞与肿瘤细胞间的复杂相互作用，为理解GEP-NENs的恶性演进提供了分子层面的证据。这一发现不仅丰富了神经内分泌肿瘤的生物学理论体系，也为未来开发针对Hedgehog通路的靶向治疗策略提供了关键的科学依据。

---

## 5. VAMP7依赖的内质网和线粒体蛋白晚期内体分泌影响肿瘤微环境及巨噬细胞参与

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41723185)
**期刊：** Nature communications
**PMID：** 41723185
**DOI：** 10.1038/s41467-026-69900-4

### 第一部分 原文与翻译

**英文原标题：** VAMP7-dependent late endosomal secretion of ER and mitochondrial proteins impacts the tumor microenvironment and macrophage engagement.

> **英文摘要：**
> Late endosomal secretion is an unconventional secretion mechanism that depends on the SNARE protein VAMP7. We previously showed that VAMP7 mediates the secretion of the ER protein Reticulon3. However, the functional relevance and molecular mechanism of this secretory pathway remain unclear. Here, we show that VAMP7 knockout cells exhibit impaired secretion of ER- and mitochondrial-derived proteins and signs of ER and mitochondrial stress. In addition, pharmacological induction of organellar stress enhances the VAMP7-dependent secretion. We assess the pathophysiological significance of this mechanism using a preclinical glioblastoma model. VAMP7 knockout glioblastoma cells implanted in male rat brain develop into more necrotic tumors with reduced macrophage infiltration compared to controls, suggesting that VAMP7-dependent late endosomal secretion contributes to the tumor microenvironment and affects macrophage infiltration. Together, our results support a model in which late endosomal secretion functions as an organelle quality-control and stress-communication mechanism, with particular relevance to cancer.

> **中文摘要：**
> 晚期内体分泌是一种依赖于SNARE蛋白VAMP7的非常规分泌机制。我们之前表明，VAMP7介导内质网蛋白Reticulon3的分泌。然而，该分泌途径的功能相关性和分子机制仍不清楚。在此，我们展示了VAMP7敲除细胞表现出内质网和线粒体来源蛋白的分泌受损，以及内质网和线粒体应激的迹象。此外，细胞器的药理性应激诱导增强了VAMP7依赖性的分泌。我们利用临床前胶质母细胞瘤模型评估了该机制的病理生理学意义。与对照组相比，植入雄性大鼠脑部的VAMP7敲除胶质母细胞瘤细胞发育成坏死程度更高的肿瘤，且巨噬细胞浸润减少，这表明VAMP7依赖的晚期内体分泌有助于肿瘤微环境的构建并影响巨噬细胞的浸润。总之，我们的研究结果支持这样一个模型：晚期内体分泌作为一种细胞器质量控制和应激通讯机制发挥作用，在癌症中具有特别重要的意义。

### 第二部分 AI 大师评价

该研究揭示了由SNARE蛋白VAMP7介导的非常规分泌途径在细胞器稳态调节中的关键作用。通过敲除实验和临床前胶质母细胞瘤模型，作者证明了这一机制是内质网与线粒体应对细胞器压力并进行质量控制的重要手段。研究阐明了该分泌途径如何通过塑造肿瘤微环境来影响巨噬细胞浸润，为理解肿瘤免疫逃逸及开发新型癌症治疗策略提供了重要的分子机制参考。

---

## 6. DNMT2通过下调5'tiRNA的产生抑制间变性甲状腺癌的进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41723159)
**期刊：** Cell death & disease
**PMID：** 41723159
**DOI：** 10.1038/s41419-026-08488-5

### 第一部分 原文与翻译

**英文原标题：** DNMT2 inhibits anaplastic thyroid cancer progression by downregulating 5'tiRNA production.

> **英文摘要：**
> Complex tRNA methylation modifications collectively maintain the structural integrity and functional efficiency of tRNA. DNA methyltransferase 2 (DNMT2) regulates the m5C methylation status of tRNA, thereby reprogramming its structure and influencing cancer progression. However, the precise mechanisms through which DNMT2 affects tumor development via tRNA methylation remain insufficiently understood. In this study, we demonstrate that reduced DNMT2 expression promotes the progression of anaplastic thyroid carcinoma (ATC). Specifically, in ATC, DNMT2 catalyzes m5C38 methylation on three tRNAs: tRNA-Asp-GUC, tRNA-Gly-GCC, and tRNA-Val-AAC. Loss of DNMT2 leads to an increased abundance of 5'tiRNA, generated by ANG-mediated cleavage of m5C38-hypomethylated tRNA-Gly-GCC. This 5'tiRNA directly binds to hnRNPH1, resulting in a reduction of its protein levels. Moreover, combined treatment with a 5'tiRNA inhibitor and doxorubicin hydrochloride significantly suppresses ATC progression in vivo. Thus, decreased DNMT2 expression facilitates ATC development by promoting the production of 5'tiRNA. Our findings also highlight the considerable therapeutic potential of targeting 5'tiRNA in the treatment of ATC.

> **中文摘要：**
> 复杂的tRNA甲基化修饰共同维持tRNA的结构完整性和功能效率。DNA甲基转移酶2 (DNMT2) 调节tRNA的m5C甲基化状态，从而重塑其结构并影响癌症进展。然而，DNMT2通过tRNA甲基化影响肿瘤发展的确切机制尚不充分。在本研究中，我们证明DNMT2表达降低会促进间变性甲状腺癌 (ATC) 的进展。具体而言，在ATC中，DNMT2催化三种tRNA（tRNA-Asp-GUC、tRNA-Gly-GCC和tRNA-Val-AAC）的m5C38位点甲基化。DNMT2的缺失导致5'tiRNA丰度增加，这些5'tiRNA是由ANG介导的m5C38低甲基化tRNA-Gly-GCC切割产生的。这种5'tiRNA直接结合hnRNPH1，导致其蛋白质水平降低。此外，5'tiRNA抑制剂与盐酸阿霉素的联合治疗在体内显著抑制了ATC的进展。因此，DNMT2表达降低通过促进5'tiRNA的产生来介导ATC的发展。我们的研究结果还突出了靶向5'tiRNA在治疗ATC中的巨大潜力。

### 第二部分 AI 大师评价

本研究深入揭示了DNMT2介导的tRNA m5C甲基化在间变性甲状腺癌（ATC）中的表观转录组调控机制。研究发现DNMT2缺失通过诱导tRNA-Gly-GCC发生ANG依赖性切割产生5'tiRNA，进而通过hnRNPH1调控肿瘤进展。该研究不仅阐明了DNMT2/5'tiRNA轴在ATC恶化中的关键作用，还通过体内实验论证了5'tiRNA抑制剂联合化疗的协同增效作用，为临床难治性甲状腺癌提供了新颖的治疗靶点和联合用药策略。

---

## 7. RORγt+ 抗原递呈细胞（APC）需要一个独特的顺式调节元件来诱导对饮食抗原的耐受

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41723158)
**期刊：** Nature communications
**PMID：** 41723158
**DOI：** 10.1038/s41467-026-69886-z

### 第一部分 原文与翻译

**英文原标题：** RORγt APCs require a distinct cis-regulatory element to instruct tolerance to dietary antigens.

> **英文摘要：**
> Oral tolerance represents a hallmark of intestinal mucosal immunity to prevent inflammatory responses to harmless natural antigens, such as dietary components or commensal organisms. According to recent studies, RORγt antigen-presenting cell (APC) contributes to intestinal homeostasis, including oral tolerance, through inducing microbiota- and dietary antigen-specific Tregs. Here we identify a cis transcriptional regulatory element that distinguishes RORγt APCs from other of RORγt cell types. This sequence within Rorc gene loci, OCR369 governs RORγt expression in ILC3s and other RORγt APCs, but not T cells, through interaction with RUNX3 and formation of chromatin loops. OCR369 deletion results in a significant reduction of RORγt APCs in mLN around the weaning period and ILC3s in mLN and intestines of adult mice, accompanied by a decrease in RORγt Tregs and spontaneous inflammation in the small intestine. Mechanistically, the reduction in RORγt APCs, including both DC-like cells and MHCII ILC3s, impairs the development of both dietary antigen-specific and microbiota-specific RORγt Tregs and results in the loss of oral tolerance, thereby increasing allergy susceptibility. Thus, our findings identify a specific regulatory mechanism for RORγt expression in RORγt APCs and underscore the pivotal role of these cell types in mediating oral tolerance and maintaining intestinal health.

> **中文摘要：**
> 口服耐受是肠道黏膜免疫的一个标志，旨在防止对无害天然抗原（如饮食成分或共生生物）产生炎症反应。根据最近的研究，RORγt+ 抗原递呈细胞（APC）通过诱导微生物群和饮食抗原特异性的 Treg 细胞，对包括口服耐受在内的肠道稳态做出贡献。在此，我们鉴定出一个顺式转录调节元件，可将 RORγt+ APCs 与其他 RORγt+ 细胞类型区分开来。位于 Rorc 基因座内的这一序列 OCR369，通过与 RUNX3 相互作用并形成染色质环，调节 ILC3 和其他 RORγt+ APCs（而非 T 细胞）中的 RORγt 表达。OCR369 缺失导致断奶期前后肠系膜淋巴结（mLN）中的 RORγt+ APCs 以及成年小鼠 mLN 和肠道中的 ILC3 显著减少，并伴有 RORγt+ Tregs 减少和小肠自发性炎症。从机制上讲，包括类树突状细胞（DC-like cells）和 MHCII+ ILC3 在内的 RORγt+ APCs 减少，损害了饮食抗原特异性和微生物群特异性 RORγt+ Tregs 的发育，导致口服耐受丧失，从而增加了过敏易感性。因此，我们的研究结果确定了 RORγt+ APCs 中 RORγt 表达的特异性调节机制，并强调了这些细胞类型在介导口服耐受和维持肠道健康中的关键作用。

### 第二部分 AI 大师评价

本研究揭示了调控 RORγt+ 抗原递呈细胞发育的特异性顺式元件 OCR369 及其作用机制。通过发现 OCR369-RUNX3 相互作用介导的染色质环化，该研究阐明了 RORγt+ APCs 在诱导饮食和菌群特异性 Tregs 及维持口服耐受中的核心地位。其创新性在于从分子水平精细刻画了特定免疫细胞亚群的转录调控图谱，为防治食物过敏和肠道炎症提供了关键的理论支撑和潜在干预靶点。

---

## 8. 空间扰动测序（Spatial Perturb-seq）：完整组织架构内的单细胞功能基因组学

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41723140)
**期刊：** Nature communications
**PMID：** 41723140
**DOI：** 10.1038/s41467-026-69677-6

### 第一部分 原文与翻译

**英文原标题：** Spatial perturb-seq: single-cell functional genomics within intact tissue architecture.

> **英文摘要：**
> We develop Spatial Perturb-Seq, an in vivo CRISPR technology that interrogates multiple genes within single cells of intact tissues, compatible with both sequencing-based and probe-based spatial technologies. We apply Spatial Perturb-Seq to knock out risk genes for neurodegenerative diseases in the mouse brain, uncovering cell autonomous and cell-cell microenvironmental effects within the spatially intact tissue. Spatial Perturb-Seq functionally screens multiple genes in situ and in vivo, bypasses cell processing steps that skew cell type representation, identifies intracellular and intercellular effects of knockouts, and identifies candidate genes underlying dysregulated neuronal intercellular communication pathways.

> **中文摘要：**
> 我们开发了空间扰动测序（Spatial Perturb-Seq），这是一种体内 CRISPR 技术，可在完整组织的单细胞内探查多个基因，并与基于测序和基于探针的空间技术相兼容。我们应用空间扰动测序在小鼠大脑中敲除神经退行性疾病的风险基因，揭示了空间完整组织内的细胞自主效应和细胞间微环境效应。空间扰动测序在原位和体内对多个基因进行功能筛选，绕过了会扭曲细胞类型表征的细胞处理步骤，识别了敲除后的细胞内和细胞间效应，并确定了神经元间通讯途径失调的候选基因。

### 第二部分 AI 大师评价

该研究开发了一种名为Spatial Perturb-Seq的创新体内CRISPR筛选技术，实现了在保持组织空间完整性的前提下进行单细胞功能基因组学研究。通过在小鼠大脑中应用，该技术成功揭示了神经退行性疾病风险基因的细胞自主性与非自主性影响。其核心优势在于规避了传统单细胞解离带来的偏差，能够精确捕获细胞间的空间互作变化，为理解复杂组织微环境中的基因功能提供了强有力的原位筛选工具。

---

## 9. α-酮戊二酸/琥珀酸比例失衡通过损伤胸腺嘧啶DNA糖苷酶功能和碱基切除修复过程增加胰腺癌易感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41723136)
**期刊：** Cell death & disease
**PMID：** 41723136
**DOI：** 10.1038/s41419-026-08475-w

### 第一部分 原文与翻译

**英文原标题：** α-ketoglutarate/succinate ratio imbalance impairs thymine DNA glycosylase function and base excision repair process increasing susceptibility to pancreatic cancer.

> **英文摘要：**
> Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, with chronic metabolic disorders increasing risk and severity. Prolonged exposure to altered metabolism changes specific metabolite levels, impacting epigenetic landscape contributing neoplastic lesion acquisition. This study examines the interplay between metabolism and epigenetics in dysmetabolic-driven PDAC tumorigenesis, exploiting LSL-KrasG12D;PDX-1-Cre mice (KC mice) exposed to high-fat diet (HFD) and KRAS-mutated human pancreatic ductal epithelial (HPDE) cells. Untargeted metabolomics of HFD-fed KC pancreata reveals altered free fatty acid and elevated S-adenosyl methionine levels during tumorigenesis. Targeted metabolomics shows increased succinate alongside reduced α-ketoglutarate levels. This imbalance suggests an epigenetic derangement, targeting DNA methylation. In KRAS-mutated HPDE cells exposed to altered metabolism, the DNA demethylation complex of ten-to-eleven-translocation methylcytosine 1 and thymine DNA glycosylase (TDG) is disrupted, leading to iterative cytosine modification and apurinic/apyrimidinic (AP) site accumulation. Succinate directly binds TDG at arginine 275, hyperactivating it and increasing AP site formation. This alteration combined with the methylation-prone metabolic environment, impairs the base excision repair pathway by hypermethylating and downmodulating DNA ligases LIG1 and LIG3. This predisposes to genomic instability and pancreatic preneoplastic lesion development. These findings uncover a metabolic-epigenetic axis in dysmetabolic PDAC, highlighting how metabolite-driven epigenetic changes compromise DNA repair and drive tumorigenesis.

> **中文摘要：**
> 胰腺导管腺癌（PDAC）是一种极具致命性的癌症，慢性代谢紊乱会增加其风险和严重程度。长期暴露于改变的代谢环境会改变特定代谢物水平，进而影响表观遗传格局，促进肿瘤性病变的获得。本研究利用暴露于高脂饮食（HFD）的LSL-KrasG12D;PDX-1-Cre小鼠（KC小鼠）和KRAS突变的人胰腺导管上皮（HPDE）细胞，探讨了代谢与表观遗传在代谢紊乱驱动的PDAC肿瘤发生中的相互作用。对喂食高脂饮食的KC小鼠胰腺进行的非靶向代谢组学研究揭示，在肿瘤发生过程中游离脂肪酸水平发生改变且S-腺苷甲硫氨酸水平升高。靶向代谢组学显示，在α-酮戊二酸水平降低的同时，琥珀酸水平有所增加。这种失衡暗示了表观遗传紊乱，主要针对DNA甲基化。在暴露于代谢改变的KRAS突变HPDE细胞中，ten-to-eleven-translocation甲基胞嘧啶1与胸腺嘧啶DNA糖苷酶（TDG）组成的DNA去甲基化复合物受到破坏，导致反复的胞嘧啶修饰和脱嘌呤/脱嘧啶（AP）位点积累。琥珀酸直接结合TDG的精氨酸275位点，使其过度激活并增加AP位点的形成。这种改变结合易于甲基化的代谢环境，通过使DNA连接酶LIG1和LIG3高甲基化并下调其表达，从而损伤了碱基切除修复途径。这导致了基因组不稳定性以及胰腺癌前病变的发展。这些发现揭示了代谢紊乱PDAC中的代谢-表观遗传轴，强调了代谢物驱动的表观遗传变化如何损害DNA修复并驱动肿瘤发生。

### 第二部分 AI 大师评价

本研究深入探讨了代谢失衡在胰腺导管腺癌（PDAC）早期发生中的分子机制，重点揭示了α-酮戊二酸与琥珀酸比例失调如何驱动表观遗传异常。通过体内外实验模型，研究发现琥珀酸能直接结合并过度激活TDG蛋白导致AP位点积累，同时配合高甲基化环境抑制DNA连接酶LIG1/3，从而损伤碱基切除修复路径。该发现确立了“代谢-表观遗传轴”在PDAC前驱病变形成中的关键地位，为代谢相关癌症的预防和早期干预提供了潜在的新靶点。

---

## 10. 肥大细胞来源的神经生长因子驱动膀胱癌中 ILC2 的促肿瘤功能

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41723132)
**期刊：** Nature communications
**PMID：** 41723132
**DOI：** 10.1038/s41467-026-69841-y

### 第一部分 原文与翻译

**英文原标题：** Mast-cell derived nerve growth factor drives ILC2 pro-tumoral functions in bladder cancer.

> **英文摘要：**
> Innate lymphoid cells type 2 (ILC2s) are key regulators of tissue homeostasis and inflammation. In cancer, ILC2s can exhibit pro-tumoral functions by increasing the myeloid derived suppressor cells (MDSC)/T-cell ratio. Nevertheless, the upstream ILC2 triggers remain poorly defined. Here, we identify nerve growth factor (NGF) as the driver of ILC2 pro-tumoral functions in patients with bladder cancer. We show that ILC2s express the NGF receptor TrkA and respond to NGF by secreting type-2 cytokines. In the tumor microenvironment, NGF-producing mast cells accumulate and activate ILC2s to induce regulatory T cells (Tregs), ultimately fostering tumor growth. In patients, NGF levels inversely correlate with survival in ILC2-rich tumors, underscoring the clinical significance of this axis. In vivo administration of a selective TrkA inhibitor improves survival in orthotopic tumor-bearing female mice and sensitizes them to immune checkpoint blockade (ICB). Overall, we identify NGF as an ILC2 activator that shapes pro-tumoral ILC2 functions. The blockade of TrkA ILC2s might represent a targetable strategy to improve survival, particularly in ICB-resistant patients.

> **中文摘要：**
> 2型固有淋巴细胞（ILC2s）是组织稳态和炎症的关键调节因子。在癌症中，ILC2s可通过增加髓源性抑制细胞（MDSC）与T细胞的比例来表现出促肿瘤功能。然而，ILC2的上游触发因素仍不清楚。在此，我们确定神经生长因子（NGF）是膀胱癌患者中ILC2促肿瘤功能的驱动因素。我们证明ILC2s表达NGF受体TrkA，并通过分泌2型细胞因子对NGF作出反应。在肿瘤微环境中，产生NGF的肥大细胞积聚并激活ILC2s以诱导调节性T细胞（Tregs），最终促进肿瘤生长。在患者中，NGF水平与ILC2丰富的肿瘤患者的生存率呈负相关，强调了这一轴的临床意义。体内给予选择性TrkA抑制剂可提高原位荷瘤雌性小鼠的生存率，并使其对免疫检查点阻断（ICB）敏感。总之，我们将NGF鉴定为一种塑造促肿瘤ILC2功能的ILC2激活因子。阻断TrkA ILC2s可能代表一种提高生存率的可靶向策略，特别是对于ICB耐药患者。

### 第二部分 AI 大师评价

本研究揭示了肥大细胞通过分泌神经生长因子（NGF）激活ILC2，进而诱导Treg细胞产生并促进膀胱癌进展的新机制。研究通过临床样本和动物实验，阐明了NGF/TrkA/ILC2轴在调节肿瘤微环境免疫抑制中的关键作用。发现TrkA抑制剂不仅能延长生存期，还能增强免疫检查点阻断疗法的敏感性，为治疗ICB耐药的膀胱癌提供了新的潜在靶点和免疫联合治疗策略。

---

## 11. 用于体外和细胞内蛋白质乙酰化研究的不可水解乙酰赖氨酸类似物

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41723125)
**期刊：** Nature communications
**PMID：** 41723125
**DOI：** 10.1038/s41467-026-69782-6

### 第一部分 原文与翻译

**英文原标题：** Non-hydrolyzable acetyllysine analogs to study protein acetylation in vitro and in cells.

> **英文摘要：**
> Lysine acetylation plays a prominent regulatory role in eukaryotic cells. Yet, determining the functional consequences of acetylation for a given protein represents a considerable challenge. For instance, lysine residues are subject to various posttranslational modifications, rendering interpretation of mutational studies difficult. The genetic code expansion technology enables site-specific incorporation of acetyllysine (AcK) into proteins, but the applicability of AcK is limited, as within cells, the acetyl group is removed by deacetylases. Here, we show that site-specific incorporation of the non-hydrolyzable AcK analog ketolysine (KeK) into ubiquitin closely resembles the structural and functional effects of AcK incorporation. Furthermore, AcK and KeK can be efficiently incorporated into the tumor suppressor p53 in cells. However, whereas AcK becomes deacetylated, KeK remains stable. Accordingly, incorporation of KeK, but not AcK, affects p53-mediated transcription. Thus, we propose that KeK is a well-suited AcK surrogate for studying acetylation of a given protein in cells.

> **中文摘要：**
> 赖氨酸乙酰化在真核细胞中发挥着重要的调节作用。然而，确定特定蛋白质乙酰化的功能后果仍面临巨大的挑战。例如，赖氨酸残基易受多种翻译后修饰的影响，使得突变研究的解释变得困难。遗传密码扩充技术能够将乙酰赖氨酸 (AcK) 位点特异性地整合到蛋白质中，但 AcK 的适用性受到限制，因为在细胞内，乙酰基会被去乙酰化酶移除。在此，我们展示了将不可水解的 AcK 类似物酮赖氨酸 (KeK) 位点特异性地整合到泛素中，其结构和功能效应与 AcK 的整合高度相似。此外，AcK 和 KeK 均可高效地整合到细胞内的肿瘤抑制因子 p53 中。然而，AcK 会发生去乙酰化，而 KeK 则保持稳定。因此，整合 KeK（而非 AcK）会影响 p53 介导的转录。因此，我们认为 KeK 是一种非常适合用于研究细胞内特定蛋白质乙酰化的 AcK 替代物。

### 第二部分 AI 大师评价

本研究针对细胞内去乙酰化酶导致乙酰化研究困难的痛点，开发并验证了不可水解的乙酰赖氨酸类似物——酮赖氨酸（KeK）。通过在泛素和p53蛋白上的实验，证明了KeK不仅在结构和功能上能完美模拟天然乙酰化，更重要的是其在细胞环境下具有极高的代谢稳定性。该方法为在活细胞中精确解析特定位点乙酰化的生物学效应提供了一种强有力的化学生物学工具，具有重要的应用价值。

---

## 12. 肿瘤细胞“村落”定义了肝癌中肿瘤与微环境的相互依赖性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41723121)
**期刊：** Nature communications
**PMID：** 41723121
**DOI：** 10.1038/s41467-026-69797-z

### 第一部分 原文与翻译

**英文原标题：** Tumor cell villages define the co-dependency of tumor and microenvironment in liver cancer.

> **英文摘要：**
> Spatial cellular context is crucial in shaping intratumor heterogeneity. However, understanding how each tumor establishes its unique spatial landscape and what factors drive the landscape for tumor fitness remains significantly challenging. Here, we analyze over 2 million cells from 50 tumor biospecimens using spatial single-cell imaging and single-cell RNA sequencing. We develop a deep learning-based strategy to spatially map tumor cell states and their surrounding environmental architecture, and find that different tumor cell states can be organized into distinct clusters, or "villages," each supported by unique microenvironments. Notably, tumor cell villages exhibit village-specific molecular co-dependencies between tumor cells and their microenvironment and are associated with patient outcomes. Perturbation of molecular co-dependencies via random spatial shuffling of the microenvironment results in destabilization of the corresponding villages. We validate our findings using single-cell, spatial, and bulk transcriptome data from 740 liver cancer patients. This study provides insights into understanding tumor spatial landscape and its impact on tumor aggressiveness.

> **中文摘要：**
> 空间细胞背景在塑造肿瘤内异质性方面至关重要。然而，理解每种肿瘤如何建立其独特的空间景观，以及哪些因素驱动了这种景观以适应肿瘤生长，仍然具有显著挑战。在本研究中，我们利用空间单细胞成像和单细胞RNA测序技术，分析了来自50个肿瘤生物标本的超过200万个细胞。我们开发了一种基于深度学习的策略，对肿瘤细胞状态及其周围环境架构进行空间制图，并发现不同的肿瘤细胞状态可以组织成不同的集群，即“村落（villages）”，每个村落都由独特的微环境支持。值得注意的是，肿瘤细胞村落表现出肿瘤细胞与其微环境之间特定的分子相互依赖性，并与患者的临床预后相关。通过对微环境进行随机空间重组来扰动分子相互依赖性，会导致相应村落的去稳定性。我们利用来自740名肝癌患者的单细胞、空间和体转录组数据验证了我们的发现。本研究为理解肿瘤空间景观及其对肿瘤侵袭性的影响提供了深刻见解。

### 第二部分 AI 大师评价

本研究通过整合空间单细胞成像与单细胞转录组学，提出了“肿瘤细胞村落（villages）”这一创新概念，揭示了肝癌中特定肿瘤细胞状态与其微环境构架间的精准耦合关系。研究利用深度学习算法在大规模样本中识别出这些空间功能单元，并证明了其分子相互依赖性是维持肿瘤组织稳态及影响临床预后的关键因素。这一发现不仅深化了对肿瘤空间异质性的理解，也为解析肿瘤微环境的共进化机制提供了新的理论框架和计算方法。

---

## 13. 肿瘤相关成纤维细胞通过 METTL1 介导的 NET1 m7G 修饰促进非小细胞肺癌细胞对奥希替尼的耐药性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41723107)
**期刊：** Cell death & disease
**PMID：** 41723107
**DOI：** 10.1038/s41419-026-08505-7

### 第一部分 原文与翻译

**英文原标题：** Cancer-associated fibroblasts promote osimertinib resistance in non-small cell lung cancer cells via METTL1-mediated NET1 mG modification.

> **英文摘要：**
> Osimertinib resistance remains a major challenge in the treatment of non-small cell lung cancer (NSCLC). Cancer-associated fibroblasts (CAFs) are the most abundant stromal cells in tumor microenvironment (TME), however, its role in osimertinib resistance in NSCLC is not fully understood. In this study, it was found that CAFs promoted osimertinib resistance in NSCLC cells via elevating RNA mG modification. Methyltransferase 1 (METTL1) in NSCLC cells mediated CAFs' effect on mG modification, and METTL1 was associated with NSCLC progression and poor prognosis. Further study demonstrates that CAFs upregulated METTL1 in NSCLC cells by secreting HMGB1. By applying MeRIP-seq and RNA-seq, neuroepithelial cell transforming gene 1 (NET1) was identified as a target of METTL1, and enhanced mG modification of NET1 increased NET1 expression and activated downstream AKT/NF-κB pathway. Importantly, reducing mG modification by METTL1 knockdown significantly attenuated CAFs' stimulatory effect on osimertinib resistance both in vitro and in vivo. Our study revealed a novel mechanism that CAFs conferred osimertinib resistance in NSCLC cells through modulating mG modification. These findings underscore the importance of mG modification in the communication between cancer cells and the TME, and pave the way for finding novel therapeutic strategies to overcome drug resistance by targeting mG modification.

> **中文摘要：**
> 奥希替尼耐药仍是非小细胞肺癌（NSCLC）治疗中的主要挑战。肿瘤相关成纤维细胞（CAFs）是肿瘤微环境（TME）中含量最丰富的基质细胞，然而其在 NSCLC 奥希替尼耐药中的作用尚未完全阐明。在本研究中，发现 CAFs 通过提高 RNA m7G 修饰水平促进 NSCLC 细胞产生奥希替尼耐药性。NSCLC 细胞中的甲基转移酶 1（METTL1）介导了 CAFs 对 m7G 修饰的影响，且 METTL1 与 NSCLC 的进展及不良预后相关。进一步研究表明，CAFs 通过分泌 HMGB1 上调 NSCLC 细胞中的 METTL1。通过应用 MeRIP-seq 和 RNA-seq，研究确定神经上皮细胞转化基因 1（NET1）为 METTL1 的靶标，且 NET1 的 m7G 修饰增强增加了其表达并激活了下游 AKT/NF-κB 通路。重要的是，通过敲低 METTL1 减少 m7G 修饰，在体内和体外均显著减弱了 CAFs 对奥希替尼耐药的刺激作用。我们的研究揭示了一种新机制，即 CAFs 通过调节 m7G 修饰赋予 NSCLC 细胞奥希替尼耐药性。这些发现强调了 m7G 修饰在癌细胞与 TME 间通讯的重要作用，并为通过靶向 m7G 修饰寻找克服耐药性的新型治疗策略奠定了基础。

### 第二部分 AI 大师评价

该研究深入探讨了肿瘤微环境与肿瘤细胞间的表观转录组互动，揭示了 CAFs 通过分泌 HMGB1 诱导 NSCLC 细胞中 METTL1 表达的分子路径。研究利用 MeRIP-seq 等技术精准鉴定了 NET1 作为 m7G 修饰的关键靶点，并证实了其对 AKT/NF-κB 通路的激活作用。这项工作不仅阐明了奥希替尼获得性耐药的新机制，还为靶向 RNA 甲基化修饰以克服肺癌耐药提供了坚实的实验依据和潜在的治疗靶点。

---

## 14. 用于分析蛋白质瓜氨酸化动态的高通量化学蛋白质组学工作流程

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41723106)
**期刊：** Nature communications
**PMID：** 41723106
**DOI：** 10.1038/s41467-026-69490-1

### 第一部分 原文与翻译

**英文原标题：** High-throughput chemical proteomics workflow for profiling protein citrullination dynamics.

> **英文摘要：**
> Citrullination is a post-translational modification implicated in autoimmune and inflammatory diseases, yet its low abundance and lack of effective enrichment tools have limited proteome-wide analysis. Here, we develop a robust chemical proteomics workflow with improved specificity and throughput. This method builds upon glyoxal-based derivatization and incorporates a cleavable biotin linker for efficient peptide enrichment, release, and identification via mass spectrometry. Benchmarking demonstrates a > 10-fold increase in the detection of citrullinated peptides at sub-0.1% abundance. Applying this workflow to primary human neutrophils, we successfully monitor dynamic regulation, quantifying dose-dependent activation and inhibition by the PAD4 inhibitor GSK484. Furthermore, stimulation with the fungal pathogen Candida albicans reveals a "core citrullinome" conserved across distinct stimuli. Notably, extensive citrullination of linker histone H1 and structural proteins like lamin B1 suggests broad remodeling of cell architecture during NET formation. This workflow enables proteome-wide mapping of citrullination sites and facilitates its study across diverse biological contexts.

> **中文摘要：**
> 瓜氨酸化是一种涉及自身免疫性疾病和炎症性疾病的翻译后修饰，但其丰度低且缺乏有效的富集工具，限制了全蛋白质组范围内的分析。在此，我们开发了一种具有改进特异性和通量的稳健化学蛋白质组学工作流程。该方法基于乙二醛衍生化，并结合了可切割的生物素接头，用于通过质谱法进行高效的肽段富集、释放和鉴定。基准测试表明，在丰度低于0.1%的情况下，瓜氨酸化肽段的检测量增加了10倍以上。将该工作流程应用于原代人中性粒细胞，我们成功监测了其动态调节，量化了PAD4抑制剂GSK484的剂量依赖性激活和抑制作用。此外，用真菌病原体白色念珠菌（Candida albicans）进行的刺激揭示了在不同刺激下保守的“核心瓜氨酸化组”。值得注意的是，接头组蛋白H1和核纤层蛋白B1等结构蛋白的广泛瓜氨酸化表明，在中性粒细胞胞外陷阱（NET）形成期间，细胞结构发生了广泛的重塑。该工作流程实现了瓜氨酸化位点的全蛋白质组制图，并促进了其在不同生物背景下的研究。

### 第二部分 AI 大师评价

该研究针对蛋白质瓜氨酸化丰度低、富集难的瓶颈，开发了一种基于乙二醛衍生化和可切割接头的高通量化学蛋白质组学工作流程。该方法显著提升了检测灵敏度，实现了对极低丰度瓜氨酸化肽段的精准富集，并在原代中性粒细胞中成功验证了其动态监测能力。通过揭示不同刺激下的“核心瓜氨酸化组”以及NET形成过程中的关键结构蛋白修饰，该研究为深入理解自身免疫与炎症相关疾病的分子机制提供了强有力的技术支撑。

---

## 15. 日本辅助超声策略性癌症随机对照试验（J-START）中40-49岁女性晚期乳腺癌的累积发病率：一项预设的次要分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41722967)
**期刊：** Lancet (London, England)
**PMID：** 41722967
**DOI：** 10.1016/S0140-6736(25)02319-0

### 第一部分 原文与翻译

**英文原标题：** Cumulative incidence of advanced breast cancer in women aged 40-49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis.

> **英文摘要：**
> BACKGROUND: The J-START randomised controlled trial found that adjunctive ultrasonography was associated with significantly higher rates of breast cancer detection than mammography alone. This report aims to evaluate the long-term effect of adjunctive ultrasonography screening on the cumulative incidence of advanced breast cancer as a prespecified secondary outcome of J-START. METHODS: We enrolled asymptomatic women in 42 study sites in 23 of 47 prefectures in Japan. Eligible women were aged 40-49 years without a history of breast cancer, including in-situ cancer, or other cancers in the previous 5 years, and who had a life expectancy of more than 5 years. Participants were assigned in a 1:1 ratio to undergo ultrasonography with mammography (intervention group) or mammography alone (control group) twice during a 2-year screening period by individual or cluster randomisation. Participants attended an initial screening appointment and were then asked to return for a second screening after 2 years. This prespecified secondary analysis assessed the cumulative incidence of stage 2 or higher breast cancers based on the TNM classification up to data cutoff on Oct 4, 2024. FINDINGS: Between Aug 2, 2007, and March 31, 2011, 72 661 asymptomatic women aged 40-49 years were randomly assigned (36 723 in the intervention group and 35 938 in the control group). Median follow-up for this secondary analysis was 11·4 years (range 0·0-16·1; IQR 9·3-12·9) in the intervention group and 11·3 years (0·0-16·1; 8·9-12·9) in the control group. Of 894 breast cancers detected in the intervention group, 234 (26%) were advanced cancers, compared with 277 (33%) of 843 detected breast cancers in the control group (hazard ratio 0·83 [95·6% CI 0·70-0·98]; p=0·026). Kaplan-Meier curves suggested a violation of the proportional hazards assumption, with a significant difference in advanced cancer incidence only between 48 months and 96 months. Divergence between groups emerged around year four, widened until year eight, and remained stable thereafter. INTERPRETATION: Adjunctive ultrasonography reduced the cumulative incidence of advanced breast cancer in women aged 40-49 years. These findings highlight the potential value of integrating adjunctive ultrasonography into screening programmes for women with dense breast tissue, particularly in Asian populations, and could inform future breast cancer screening guidelines. FUNDING: The Ministry of Health, Labor, and Welfare (Japan) and Japan Agency for Medical Research and Development.

> **中文摘要：**
> 背景：J-START随机对照试验发现，与仅行乳腺X线检查相比，辅助超声检查与显著更高的乳腺癌检出率相关。本报告旨在评估辅助超声筛查对晚期乳腺癌累积发病率的长期影响，这是J-START试验的一项预设次要结局。方法：我们在日本47个都道府县中的23个共42个研究中心招募了无症状女性。符合条件的女性年龄为40-49岁，无乳腺癌病史（包括原位癌），且在过去5年内无其他癌症病史，预期寿命超过5年。参与者通过个人或集群随机化，按1:1的比例被分配在为期2年的筛查期内接受两次超声联合乳腺X线检查（干预组）或仅接受两次乳腺X线检查（对照组）。参与者参加初始筛查后，被要求在2年后返回进行第二次筛查。这项预设的次要分析评估了截至2024年10月4日数据截止日，基于TNM分期的2期或更高分期乳腺癌的累积发病率。结果：在2007年8月2日至2011年3月31日期间，72,661名40-49岁的无症状女性被随机分配（干预组36,723人，对照组35,938人）。本次次要分析的干预组中位随访时间为11.4年（范围0.0-16.1；四分位距[IQR] 9.3-12.9），对照组为11.3年（0.0-16.1；8.9-12.9）。在干预组检出的894例乳腺癌中，234例（26%）为晚期癌症，而对照组检出的843例乳腺癌中，有277例（33%）为晚期癌症（风险比0.83 [95.6% CI 0.70-0.98]；p=0.026）。Kaplan-Meier曲线提示违反了比例风险假设，晚期癌症发病率仅在48个月至96个月之间存在显著差异。两组之间的差异在第4年左右出现，在第8年之前扩大，此后保持稳定。解释：辅助超声降低了40-49岁女性晚期乳腺癌的累积发病率。这些发现强调了将辅助超声整合到乳腺组织致密女性（尤其是亚洲人群）筛查项目中的潜在价值，并可为未来的乳腺癌筛查指南提供信息。资助：日本厚生劳动省和日本医疗研究开发机构。

### 第二部分 AI 大师评价

本研究是J-START试验的一项关键性长期随访分析，通过长达11年的数据填补了辅助超声能否降低晚期乳腺癌发病率这一重要的循证医学空白。结果显示，对于40-49岁女性（尤其是致密型乳腺高发的亚洲人群），辅助超声显著降低了晚期乳腺癌（II期及以上）的累积风险（HR 0.83），且这种保护效应在筛查后4至8年最为显著。尽管研究存在比例风险假设不成立等局限，但其为乳腺癌筛查指南中引入超声作为补充手段提供了强有力的支持。

---

## 16. 补充超声筛查可降低晚期乳腺癌的检出率

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41722959)
**期刊：** Lancet (London, England)
**PMID：** 41722959
**DOI：** 10.1016/S0140-6736(26)00110-8

### 第一部分 原文与翻译

**英文原标题：** Supplemental ultrasound screening lowers advanced breast cancers.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无可用摘要。

### 第二部分 AI 大师评价

该研究主要探讨了补充超声检查在乳腺癌筛查中的临床应用价值。其核心发现表明，在常规筛查基础上增加超声检查能够显著降低晚期乳腺癌的发生比例，这对于改善患者预后具有重要意义。虽然原始文献未提供详细摘要，但标题明确揭示了其在提升早期诊断率和优化公共卫生筛查策略方面的贡献。这一发现为针对致密型乳腺人群制定更为精准的个体化筛查方案提供了有力的循证医学证据。

---

## 17. 脂肪细胞来源的外泌体 miR-5099 通过 c-Met/NF-κB 轴减轻 M1 型巨噬细胞极化和脂肪炎症以改善代谢健康

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41722058)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41722058
**DOI：** 10.1002/advs.202518902

### 第一部分 原文与翻译

**英文原标题：** Adipocyte-Derived Exosomal miR-5099 Mitigates M1 Macrophage Polarization and Adipose Inflammation via c-Met/NF-κB Axis to Improve Metabolic Health.

> **英文摘要：**
> Obesity underlies metabolic dysfunction and contributes to the pathogenesis of various diseases. Obesity associated adipose tissue (AT) inflammation contributes to whole body inflammation vulnerability and metabolic disease development. Celastrol (CEL) exhibits significant therapeutic potential against obesity; however, its clinical application is limited by toxicity. Here, CEL treatment fundamentally reprograms the microRNA (miRNA) profile of adipocyte-derived exosomes. Among the altered miRNAs, we identified miR-5099 as being dramatically upregulated and enriched specifically within adipocyte-derived exosomes. We found that CEL-conditioned adipocyte culture medium exhibited the beneficial effects, including the suppression of M1 macrophage polarization, improvement of metabolic function, and reduction of inflammation in obese animals. Importantly, these beneficial effects are largely dependent on the presence of exosomal miR-5099. Furthermore, direct administration of miR-5099 in obese mice significantly ameliorated metabolic disorders, including adipose tissue inflammation and hepatic steatosis. Mechanistically, miR-5099 attenuates AT inflammation by directly targeting the c-Met/NF-κB axis in infiltrated macrophages. Concomitantly, miR-5099 enhances systemic insulin sensitivity and glucose homeostasis across metabolic tissues. Collectively, our study identifies miR-5099 as the key downstream effector of CEL. This finding suggests that direct miR-5099 administration offers a strategy to harness the therapeutic benefits of CEL while circumventing its toxicity, positioning it as a promising treatment for obesity and associated comorbidities.

> **中文摘要：**
> 肥胖是代谢功能障碍的基础，并促成各种疾病的发病机制。与肥胖相关的脂肪组织（AT）炎症会导致全身炎症易感性和代谢性疾病的发展。雷公藤红素（CEL）在抗肥胖方面表现出显著的治疗潜力；然而，其临床应用受限于其毒性。在本研究中，CEL 处理从根本上重构了脂肪细胞来源外泌体的微小 RNA（miRNA）图谱。在改变的 miRNA 中，我们发现 miR-5099 显著上调，并特异性地富集在脂肪细胞来源的外泌体中。我们发现，CEL 预处理的脂肪细胞培养基表现出有益作用，包括抑制 M1 型巨噬细胞极化、改善代谢功能以及减轻肥胖动物的炎症。重要的是，这些有益作用在很大程度上依赖于外泌体 miR-5099 的存在。此外，在肥胖小鼠中直接施用 miR-5099 可显著改善代谢紊乱，包括脂肪组织炎症和肝脂肪变性。从机制上讲，miR-5099 通过直接靶向浸润巨噬细胞中的 c-Met/NF-κB 轴来减轻脂肪组织炎症。与此同时，miR-5099 增强了代谢组织的全身胰岛素敏感性和葡萄糖稳态。总之，我们的研究确定 miR-5099 是 CEL 的关键下游效应因子。这一发现表明，直接施用 miR-5099 提供了一种利用 CEL 治疗获益同时规避其毒性的策略，使其成为治疗肥胖及其相关合并症的一种有前景的方法。

### 第二部分 AI 大师评价

该研究深入探讨了雷公藤红素（Celastrol）抗肥胖的分子机制，发现脂肪细胞分泌的含有 miR-5099 的外泌体是其发挥代谢调节作用的关键效应介质。通过揭示 miR-5099 靶向 c-Met/NF-κB 轴抑制 M1 巨噬细胞极化的通路，该研究不仅阐明了 CEL 重塑脂肪组织微环境的新途径，还提出了一种利用外泌体 miRNA 开发低毒性、高针对性抗肥胖疗法的新策略，具有显著的临床转化潜力和科学价值。

---

## 18. 泛癌突变不耐受精细映射鉴定 CHEK1 为肺腺癌中的免疫抑制驱动因子

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41722056)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41722056
**DOI：** 10.1002/advs.202521265

### 第一部分 原文与翻译

**英文原标题：** Pancancer Fine-Mapping of Mutational Intolerance Identifies CHEK1 as an Immunosuppressive Driver in Lung Adenocarcinoma.

> **英文摘要：**
> Mutation-intolerant genes (MIGs), which are constrained in tumors yet variable in normal tissues, are critical for cancer survival. Herein, we developed miDriver, a computational framework using pancancer-normal mutation contrasts to identify 1,020 MIGs across 8,096 tumors of 13 cancer types. Strikingly, MIGs are highly associated with synthetic lethality, cell-cycle progression, and clinical outcome. CRISPR screening reveals MIGs, especially CHEK1, as cancer-specific vulnerabilities, whose suppression impairs tumor proliferation and migration. Single-cell transcriptomics reveals a CHEK1-high subpopulation exhibiting stem-like and immune-suppressed features, linking tumor-intrinsic fitness to microenvironment remodeling. Multiplexed immunofluorescence revealed that CHEK1 and MIF are co-expressed in tumor cells, and CHEK1-high tumor cells exhibit closer spatial proximity to M2-like macrophages. Mechanistically, CHEK1 promotes p53 phosphorylation to upregulate MIF expression and secretion, thereby driving M2-like macrophage polarization via the MIF-CD74 axis. In vivo, targeting the CHEK1-MIF axis (particularly CHEK1) broadly reverses immunosuppression. Clinically, higher tumor CHEK1 levels are associated with poorer response to anti-PD-1 therapy. Exemplified by CHEK1, these findings establish MIGs as dual therapeutic targets capable of simultaneously disrupting tumor-intrinsic fitness and remodeling the immunosuppressive niche. This work proposes a novel paradigm for selectively targeting MIGs to eliminate aggressive tumor subclones while minimizing toxicity to normal cells.

> **中文摘要：**
> 突变不耐受基因 (MIGs) 在肿瘤中受到进化约束，但在正常组织中具有变异性，对癌症生存至关重要。在此，我们开发了 miDriver，这是一个利用泛癌-正常突变对比来鉴定 13 种癌症类型中 8,096 个肿瘤的 1,020 个 MIGs 的计算框架。引人注目的是，MIGs 与合成致死、细胞周期进程和临床预后高度相关。CRISPR 筛选揭示了 MIGs（特别是 CHEK1）是癌症特异性的脆弱点，抑制这些基因会损害肿瘤的增殖和迁移。单细胞转录组学揭示了一个 CHEK1 高表达的亚群，表现出干细胞样和免疫抑制特征，将肿瘤内在适应性与微环境重塑联系起来。多重免疫荧光显示 CHEK1 和 MIF 在肿瘤细胞中共表达，且 CHEK1 高表达的肿瘤细胞在空间上更接近 M2 样巨噬细胞。从机制上讲，CHEK1 促进 p53 磷酸化以诱导 MIF 表达和分泌，从而通过 MIF-CD74 轴驱动 M2 样巨噬细胞极化。在体内，靶向 CHEK1-MIF 轴（特别是 CHEK1）可广泛逆转免疫抑制。临床上，较高的肿瘤 CHEK1 水平与抗 PD-1 治疗反应较差相关。以 CHEK1 为例，这些发现证实 MIGs 是既能同时破坏肿瘤内在适应性，又能重塑免疫抑制生态位的双重治疗靶点。本研究提出了一种选择性靶向 MIGs 的新范式，旨在消除侵袭性肿瘤亚克隆，同时最大限度地减少对正常细胞的毒性。

### 第二部分 AI 大师评价

该研究开发了创新的计算框架 miDriver，通过泛癌分析鉴定出肿瘤生存必需的突变不耐受基因（MIGs），并深入揭示了 CHEK1 在肺腺癌中的驱动作用。研究不仅阐明了 CHEK1 通过 p53-MIF-CD74 轴诱导 M2 巨噬细胞极化的新机制，还论证了其作为双效靶点在抑制肿瘤内在增长与重塑免疫微环境方面的潜力。该成果为精准靶向肿瘤特异性弱点提供了重要理论依据，具有极高的临床转化价值，尤其是为克服免疫治疗耐药提供了新思路。

---

## 19. 铜死亡与双硫死亡协同作用：通过Cadict诱导的PD-L1翻译增强PD-L1检查点疗法

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41722054)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41722054
**DOI：** 10.1002/advs.202515367

### 第一部分 原文与翻译

**英文原标题：** Cuproptosis and Disulfidptosis Converge to Empower PD-L1 Checkpoint Therapy via Cadict-Induced PD-L1 Translation.

> **英文摘要：**
> Immune checkpoint blockade (ICB) has emerged as a cornerstone of cancer therapy, yet its effectiveness remains restricted in PD-L1-low malignancies due to insufficient target expression. We herein develop the cuproptosis and disulfidptosis co-delivery targeted (Cadict) nanodrug, an epidermal growth factor receptor (EGFR)-targeted nanoplatform designed to co-induce cuproptosis and disulfidptosis, thereby synergistically augmenting tumor cytotoxicity and sensitizing cancers to anti-PD-L1 therapy. Cadict exploits copper-sulfur (Cu-S) coordination chemistry to co-deliver copper ions and cystine, while integrating glucose oxidase (GOx) to create a hypoglycemic milieu essential for disulfidptosis execution. This dual cytotoxic mechanism not only triggers immunogenic cell death-like phenotype but also unexpectedly activates the integrated stress response (ISR), promoting PD-L1 upregulation through Eif5b-dependent translation. The resulting synergy between redox-driven cytotoxicity and immune modulation potentiates anti-PD-L1 efficacy, leading to robust tumor regression and durable immunological memory. Our work presents a seminal strategy that leverages tumor redox vulnerabilities to advance cancer immunotherapy, providing a new paradigm for overcoming ICB resistance via targeted tumor sensitization.

> **中文摘要：**
> 免疫检查点阻断（ICB）已成为癌症治疗的基石，但由于靶标表达不足，其在PD-L1低表达的恶性肿瘤中的疗效仍然受限。我们在此开发了铜死亡与双硫死亡协同递送靶向（Cadict）纳米药物，这是一种针对表皮生长因子受体（EGFR）设计的纳米平台，旨在共同诱导铜死亡和双硫死亡，从而协同增强肿瘤细胞毒性并使癌症对抗PD-L1治疗敏感。Cadict利用铜-硫（Cu-S）配位化学共同递送铜离子和胱氨酸，同时集成葡萄糖氧化酶（GOx）以创造执行双硫死亡所必需的低血糖环境。这种双重细胞毒性机制不仅触发了类免疫原性细胞死亡表型，还意外地激活了整合应激反应（ISR），通过Eif5b依赖性翻译促进PD-L1上调。由此产生的氧化还原驱动的细胞毒性与免疫调节之间的协同作用增强了抗PD-L1的疗效，导致强力的肿瘤消退和持久的免疫记忆。我们的工作提出了一种利用肿瘤氧化还原脆弱性来推进癌症免疫治疗的开创性策略，为通过靶向肿瘤敏化克服ICB耐药性提供了新范式。

### 第二部分 AI 大师评价

该研究创新性地构建了名为Cadict的纳米平台，通过协同诱导铜死亡和双硫死亡两种新型细胞死亡模式，解决了PD-L1低表达肿瘤对免疫检查点阻断疗法不敏感的临床痛点。研究亮点在于揭示了氧化还原压力通过激活整合应激反应（ISR）及Eif5b介导的翻译途径上调PD-L1的新机制，实现了肿瘤杀伤与免疫增敏的双重功效。实验结果证明该策略能显著诱导肿瘤消退并建立持久免疫记忆，为利用肿瘤代谢脆弱性克服免疫治疗耐药提供了极具价值的学术思路和应用范例。

---

## 20. 通过可调极化和界面缺陷工程增强光-热释电效应

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41722052)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41722052
**DOI：** 10.1002/advs.202519280

### 第一部分 原文与翻译

**英文原标题：** Boosting Photo-Pyroelectric Effect via Tunable Polarization and Interfacial Defect Engineering.

> **英文摘要：**
> Pyroelectric catalysis has shown promising prospects for sustainable energy generation and medical treatments. However, its potential is limited by intrinsically low pyroelectric coefficients and insufficient interfacial reactivity, resulting in poor reactive oxygen species (ROS) output. In this study, we design Ba(TiZr)O (BTZ) nanocatalysts, featuring enhanced polarization tunability and oxygen-vacancy-rich interfaces, for efficient NIR-II-driven photo-pyroelectric cancer therapy. Molecular dynamics and phase-field simulations indicate that Zr incorporation maintains strong polarization while facilitating rapid polarization switching via multiscale nanodomain formation. This results in an ultrahigh pyroelectric coefficient (3505 µC m K), representing a 678% enhancement over pristine BaTiO. Interface engineering introduces oxygen vacancies that enhance NIR-II photothermal conversion and serve as reactive sites to facilitate the dissociation of water molecules. Density functional theory calculations reveal that Zr doping narrows the bandgap and redistributes conduction band electrons, while interfacial oxygen vacancies facilitate water adsorption through optimized hydroxyl binding. As a result, synergistic pyrocatalysis and peroxidase-like activity under NIR-II-driven mild thermal cycling enable robust multipath ROS generation. Both in vitro and in vivo studies confirm efficient tumor cell ablation via NIR-II induced pyroelectric therapy. This work presents a co-engineering strategy integrating polarization and interface design to overcome long-standing limitations in pyroelectric catalysis, advancing its application in precision oncology.

> **中文摘要：**
> 热释电催化在可持续能源产生和医疗领域展现出广阔的前景。然而，其潜力受到内在低热释电系数和界面反应活性不足的限制，导致活性氧（ROS）产量较低。在本研究中，我们设计了具有增强极化可调性和富含氧空位界面的钛锆酸钡（BTZ）纳米催化剂，用于高效的第二近红外窗口（NIR-II）驱动的光-热释电癌症治疗。分子动力学和相场模拟表明，锆（Zr）的掺入在保持强极化的同时，通过形成多尺度纳米畴促进了极化的快速切换。这产生了一个超高的热释电系数（3505 µC m⁻² K⁻¹），较原始钛酸钡（BaTiO₃）提高了678%。界面工程引入了氧空位，增强了NIR-II光热转换能力，并作为反应位点促进水分子的解离。密度泛函理论计算揭示，Zr掺杂缩小了带隙并重新分布了导带电子，而界面氧空位通过优化的羟基结合促进了水分子的吸附。因此，在NIR-II驱动的温和热循环下，协同的热释电催化和类过氧化物酶活性实现了稳健的多途径ROS产生。体外和体内研究均证实，通过NIR-II诱导的热释电疗法可有效实现肿瘤细胞消融。该工作提出了一种整合极化和界面设计的协同工程策略，以克服热释电催化中长期存在的局限性，推进其在精准肿瘤学中的应用。

### 第二部分 AI 大师评价

本文针对热释电催化在肿瘤治疗中活性氧产率低的核心瓶颈，通过Zr元素掺杂与界面氧空位工程实现了材料性能的显著跨越。研究亮点在于利用多尺度纳米畴构筑将热释电系数提升了678%，并结合多物理场模拟与密度泛函理论深入揭示了能带优化与极化快速切换的物理机制。实验证实了该BTZ纳米催化剂在NIR-II驱动下具有卓越的协同催化能力，为开发高效热释电纳米药物及精准肿瘤消融提供了创新的工程化策略。

---

## 21. 肾上腺皮质肿瘤网状纤维算法的验证：评估跨所有年龄组和组织学亚型的诊断准确性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41721971)
**期刊：** Endocrine pathology
**PMID：** 41721971
**DOI：** 10.1007/s12022-026-09909-z

### 第一部分 原文与翻译

**英文原标题：** Validation of the Reticulin Algorithm for Adrenocortical Neoplasms: Assessing Diagnostic Accuracy Across All Age Groups and Histological Subtypes.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本研究聚焦于肾上腺皮质肿瘤诊断中网状纤维算法的临床验证，核心目的在于评估该算法在不同年龄群体及各类组织学亚型中的诊断效能。研究通过大规模验证，旨在解决以往诊断标准在特定亚型或儿童患者中可能存在的局限性。此项工作的开展为病理医生提供了更为稳健的鉴别诊断依据，对于推动肾上腺肿瘤诊断的标准化和精准化具有重要的临床价值。

---

## 22. 超级增强子驱动的 SOX4/SMAD3 通过调节磷脂代谢介导细胞膜重构，从而加速白血病进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41721601)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41721601
**DOI：** 10.1002/advs.202512332

### 第一部分 原文与翻译

**英文原标题：** Super-Enhancer-Driven SOX4/SMAD3 Mediate Membrane Remodeling by Regulating Phospholipid Metabolism to Accelerate Leukemia Progression.

> **英文摘要：**
> Chronic myeloid leukemia (CML) is driven by the BCR-ABL fusion oncogene and progresses from chronic phase (CP) to blast phase (BP). While tyrosine kinase inhibitors (TKIs) effectively control CML-CP, CML-BP remains a therapeutic challenge characterized by treatment resistance and poor survival. Accumulating evidence indicates that aberrant activation of epigenetic regulatory elements remodels the transcriptome in cancer, creating dependencies on specific transcriptional regulators that drive cancer progression. However, whether specific transcriptional mechanisms promote the transition from CML-CP to CML-BP remains unclear. This study identifies super-enhancer-driven transcription factors SOX4 and SMAD3 in CML-BP. SOX4 and SMAD3 engage in a positive feedback axis through mutual binding to their respective super-enhancers and promoters. Functional assays confirm that this axis promotes leukemic progression in vitro and in vivo. Mechanistically, SOX4/SMAD3 bind to the promoter and enhancer regions of the receptor tyrosine kinase AXL, enhancing its transcription and subsequently activating the AKT/ERK/STAT5 signaling. Concurrently, they transcriptionally upregulate LPCAT1, which remodels membrane phospholipids to facilitate AXL localization. Notably, the AXL inhibitor Bemcentinib effectively suppressed CML-BP progression in both in vivo and in vitro models. Collectively, our findings establish SE-driven SOX4 and SMAD3 as key regulators in CML-BP and identify Bemcentinib as a promising therapeutic strategy.

> **中文摘要：**
> 慢性髓系白血病（CML）由 BCR-ABL 融合癌基因驱动，并从慢性期（CP）进展至急变期（BP）。虽然酪氨酸激酶抑制剂（TKIs）能有效控制 CML-CP，但 CML-BP 仍是治疗上的挑战，其特点是耐药性强和生存率低。越来越多的证据表明，表观遗传调节元件的异常激活会重构癌症中的转录组，从而产生对驱动癌症进展的特定转录调节因子的依赖。然而，促进 CML-CP 向 CML-BP 转化的特定转录机制仍不明确。本研究在 CML-BP 中鉴定了超级增强子驱动的转录因子 SOX4 和 SMAD3。SOX4 和 SMAD3 通过相互结合到各自的超级增强子和启动子上，形成一个正反馈轴。功能实验证实，该轴在体外和体内均能促进白血病进展。从机制上讲，SOX4/SMAD3 结合到受体酪氨酸激酶 AXL 的启动子和增强子区域，增强其转录，并随后激活 AKT/ERK/STAT5 信号通路。同时，它们转录上调 LPCAT1，从而重构细胞膜磷脂以促进 AXL 的定位。值得注意的是，AXL 抑制剂 Bemcentinib 在体内和体外模型中均能有效抑制 CML-BP 的进展。总之，我们的研究结果确定了超级增强子驱动的 SOX4 和 SMAD3 是 CML-BP 的关键调节因子，并确定了 Bemcentinib 是一种极具前景的治疗策略。

### 第二部分 AI 大师评价

该研究深入探讨了慢性髓系白血病（CML）从慢性期向急变期转化的表观遗传机制，揭示了由超级增强子驱动的 SOX4/SMAD3 正反馈环路在驱动疾病进展中的核心作用。研究创新性地发现该轴线不仅通过转录调控 AXL 及其下游信号通路，还通过 LPCAT1 调节磷脂代谢介导膜重构，从而增强 AXL 的膜定位。实验通过体内外模型验证了 AXL 抑制剂 Bemcentinib 对 CML-BP 的治疗潜力，为克服急变期耐药和改善患者预后提供了新的分子靶点和干预策略。

---

## 23. 抗凋亡及神经突保护纳米药物增强胚胎干细胞来源的视网膜神经节细胞移植在青光眼康复中的疗效

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41721595)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41721595
**DOI：** 10.1002/advs.202513499

### 第一部分 原文与翻译

**英文原标题：** Anti-Apoptotic and Neurite-Protective Nanomedicine Augments Embryonic Stem Cells-Derived Retinal Ganglion Cell Transplantation in Glaucoma Recovery.

> **英文摘要：**
> Retinal ganglion cell (RGC) degeneration represents a cardinal etiology of irreversible vision loss in glaucoma, where efficacious regenerative therapies remain scarce. RGC replacement therapy holds promise for visual function restoration, yet its therapeutic efficacy is constrained by the hostile glaucomatous microenvironment, dominated by oxidative stress that compromises transplanted RGC survival. Here, we report the design of multifunctional lithium-epigallocatechin gallate nanoparticles (Li-EGCG NPs) to synergistically enhance antioxidant capacity and neuroprotection. These NPs exhibit uniform spherical morphology, broad-spectrum reactive oxygen species scavenging activity, and exceptional biocompatibility with embryonic stem cell-derived RGCs (ESC-RGCs). In vitro, Li-EGCG NPs mitigate oxidative stress-induced apoptosis, preserve neurite integrity, and maintain mitochondrial homeostasis in ESC-RGCs. Transcriptomic analyses reveal activation of neuroprotective pathways, including apoptosis regulation, axon guidance, and mitochondrial function. In a retinal ischemia/reperfusion injury model, which serves as an acute pathological glaucomatous injury model, combinatorial Li-EGCG NPs and ESC-RGCs transplantation markedly improves ESC-RGCs survival, preserves retinal architecture, and restores visual function beyond single-modality therapy. This study establishes Li-EGCG NPs as a robust nanomedicine platform for retinal neurodegenerative diseases, offering a promising strategy to augment cell-based therapies.

> **中文摘要：**
> 视网膜神经节细胞（RGC）变性是青光眼导致不可逆视力丧失的主要病因，而目前仍缺乏有效的再生疗法。RGC替代疗法在恢复视觉功能方面具有潜力，但其治疗效果受限于恶劣的青光眼微环境，特别是氧化应激占主导地位，严重损害了移植RGC的存活。在此，我们报道了一种多功能锂-表没食子儿茶素没食子酸酯纳米颗粒（Li-EGCG NPs）的设计，旨在协同增强抗氧化能力和神经保护作用。这些纳米颗粒表现出均匀的球形形态、广谱的活性氧清除活性，以及与胚胎干细胞来源的RGC（ESC-RGCs）卓越的生物相容性。在体外实验中，Li-EGCG NPs减轻了氧化应激诱导的凋亡，保持了神经突的完整性，并维持了ESC-RGCs中的线粒体稳态。转录组学分析揭示了神经保护途径的激活，包括凋亡调节、轴突引导和线粒体功能。在视网膜缺血/再灌注损伤模型（作为急性病理生理性青光眼损伤模型）中，Li-EGCG NPs与ESC-RGCs的联合移植显著提高了ESC-RGCs的存活率，保护了视网膜结构，并实现了优于单一疗法的视觉功能恢复。本研究确立了Li-EGCG NPs作为视网膜神经退行性疾病稳健纳米药物平台的地位，为增强细胞疗法提供了一种极具前景的策略。

### 第二部分 AI 大师评价

该研究针对青光眼细胞替代疗法中移植细胞存活率低的核心瓶颈，创新性地开发了具备抗氧化与神经保护双重功能的多功能Li-EGCG纳米颗粒。通过体外实验与急性青光眼动物模型的系统验证，该纳米平台证明能显著改善病理微环境，维持线粒体稳态并促进神经突再生。这种“纳米药物辅助细胞移植”的协同策略，不仅显著提升了ESC-RGCs的存活与功能整合，也为视网膜神经退行性疾病提供了极具临床转化潜力的联合治疗方案。

---

## 24. EZH2与DNA甲基化之间的相互作用介导神经内分泌前列腺癌的谱系可塑性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41720768)
**期刊：** Nature communications
**PMID：** 41720768
**DOI：** 10.1038/s41467-026-69308-0

### 第一部分 原文与翻译

**英文原标题：** Crosstalk between EZH2 and DNA methylation mediates neuroendocrine prostate cancer lineage plasticity.

> **英文摘要：**
> Prostate cancer lineage plasticity is associated with changes in DNA methylation and enhancer of zeste homolog 2 (EZH2) activity. How these epigenetic programs functionally interact to modulate transcriptional reprogramming in neuroendocrine prostate cancer (NEPC) is not well understood. In this study, we demonstrate that hypomethylated regions of DNA preferentially accumulate the repressive mark, H3K27me3. We established an NEPC mouse model with deletion of Ezh2 in the background of Pten and Rb1 loss plus human MYCN overexpression. Deletion or pharmacological inhibition of EZH2 in NEPC murine or patient-derived models leads to a genome-wide rewiring of DNA methylation, characterized by hypomethylation and upregulation of neuroendocrine-lineage genes along with hypermethylation and repression of polycomb repressive complex 2 (PRC2) targets. On the other hand, deletion of DNA methyltransferase 1 (DNMT1) results in significant changes in H3K27me3 distribution, particularly affecting bivalent promoters bearing both H3K27me3 and active H3K4me3 marks. In NEPC models, neuroendocrine-lineage genes are repressed upon DNMT1 deletion associated with increased H3K27me3. Conversely, in prostate adenocarcinoma models, DNMT1 deletion leads to de-repression of neuroendocrine lineage genes with a loss of H3K27me3 marks. Our findings reveal a functional interplay between two repressive epigenetic machineries that mediates lineage plasticity in prostate cancer.

> **中文摘要：**
> 前列腺癌谱系可塑性与DNA甲基化以及zeste同源物2增强子（EZH2）活性的变化相关。这些表观遗传程序如何通过功能性相互作用来调节神经内分泌前列腺癌（NEPC）中的转录重编程，目前尚不完全清楚。在本研究中，我们证明了DNA低甲基化区域优先积累抑制性标记H3K27me3。我们建立了一个在Pten和Rb1缺失以及人类MYCN过表达背景下缺失Ezh2的NEPC小鼠模型。在NEPC小鼠或患者来源的模型中，缺失或药理学抑制EZH2会导致全基因组范围内的DNA甲基化重构，其特征是神经内分泌谱系基因的低甲基化和上调，以及多梳抑制复合物2（PRC2）靶点的高甲基化和抑制。另一方面，DNA甲基转移酶1（DNMT1）的缺失导致H3K27me3分布发生显著变化，特别是影响携带H3K27me3和活性H3K4me3双重标记的双价启动子。在NEPC模型中，DNMT1缺失导致H3K27me3增加，进而抑制神经内分泌谱系基因。相反，在前列腺腺癌模型中，DNMT1缺失导致H3K27me3标记丢失，从而使神经内分泌谱系基因去抑制。我们的研究结果揭示了两种抑制性表观遗传机制之间介导前列腺癌谱系可塑性的功能性相互作用。

### 第二部分 AI 大师评价

该研究深入探讨了EZH2与DNA甲基化在前列腺癌向神经内分泌型转变过程中的协同调控机制。通过构建复杂的NEPC小鼠模型并结合患者来源样本，作者揭示了两种主要的表观遗传抑制系统如何动态互作：EZH2缺失会重构全基因组DNA甲基化图谱，而DNMT1则通过调节双价启动子上的H3K27me3分布来影响谱系特定基因的表达。研究不仅阐明了NEPC转录重组的分子基础，还揭示了腺癌与NEPC在表观遗传调控逻辑上的显著差异，为针对谱系可塑性的精准治疗提供了重要理论依据。

---

## 25. 免疫球蛋白补充和延长给药间隔可降低接受 teclistamab 治疗的 RRMM 患者的感染风险

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41720763)
**期刊：** Blood cancer journal
**PMID：** 41720763
**DOI：** 10.1038/s41408-026-01451-9

### 第一部分 原文与翻译

**英文原标题：** Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab.

> **英文摘要：**
> Patients with relapsed/refractory multiple myeloma (RRMM) who are treated with BCMA-directed bispecific antibodies (BsAbs) are at an increased risk for infections. Previous studies have shown that treatment with intravenous immunoglobulin (IVIG) reduced the risk for severe infections. However, whether IVIG also reduces all-grade infections and whether there is an impact of longer dosing intervals on infection risk remains unknown. To address this, we retrospectively investigated 80 patients with RRMM who were treated with teclistamab in a single center. After a median follow-up of 21 months, in total 390 infections were reported, of which 48 were severe. Treatment with IVIG resulted in significantly lower rates of both severe infections (0.33 vs. 0.93 per patient-year) as well as of all-grade infections (3.15 vs. 4.41 per patient-year). Multivariable analyses revealed that older age and higher beta-2-microglobulin levels were associated with an increased risk of severe breakthrough infections during IVIG supplementation. Importantly, longer dosing intervals reduced infection rates for all-grade infections (from 6.08 infections per patient-year during weekly dosing to 2.25 infections per patient-year during bimonthly dosing) and for severe infections (from 0.81 infections per patient-year during weekly dosing to 0.1 per patient-year during bimonthly dosing). These results underline the importance of the assessment of annualized infection rates to reflect the true infectious burden in patients who were treated with BCMA-directed BsAbs.

> **中文摘要：**
> 接受靶向 BCMA 双特异性抗体 (BsAbs) 治疗的复发/难治性多发性骨髓瘤 (RRMM) 患者感染风险增加。先前的研究表明，静脉注射免疫球蛋白 (IVIG) 治疗可降低严重感染的风险。然而，IVIG 是否也能减少全级别感染，以及延长给药间隔对感染风险是否有影响，目前仍不清楚。为解决这一问题，我们回顾性调查了单中心接受 teclistamab 治疗的 80 名 RRMM 患者。中位随访 21 个月后，共报告了 390 例感染，其中 48 例为严重感染。IVIG 治疗显著降低了严重感染率（0.33 对比 0.93 次/患者年）以及全级别感染率（3.15 对比 4.41 次/患者年）。多变量分析显示，在补充 IVIG 期间，高龄和较高的 β-2-微球蛋白水平与严重突破性感染风险增加相关。重要的是，延长给药间隔降低了全级别感染率（从每周给药期间的 6.08 次/患者年降至每两月给药期间的 2.25 次/患者年）以及严重感染率（从每周给药期间的 0.81 次/患者年降至每两月给药期间的 0.1 次/患者年）。这些结果强调了评估年化感染率对于反映接受 BCMA 靶向 BsAbs 治疗患者真实感染负担的重要性。

### 第二部分 AI 大师评价

本研究通过单中心回顾性分析，深入探讨了 teclistamab 治疗 RRMM 患者中 IVIG 补充和给药间隔对感染风险的影响。研究证实，IVIG 不仅能显著降低严重感染率，还对全级别感染具有保护作用，并首次明确了延长给药间隔能大幅度降低年化感染率。多变量分析揭示了突破性感染的高危因素，为 BCMA 靶向治疗的安全性管理和个体化给药策略提供了重要的循证依据。

---

## 26. 症状发作2小时内重组凝血因子VIIa对比安慰剂治疗自发性脑出血（FASTEST）：一项多中心、双盲、随机、安慰剂对照、3期试验

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41653933)
**期刊：** Lancet (London, England)
**PMID：** 41653933
**DOI：** 10.1016/S0140-6736(26)00097-8

### 第一部分 原文与翻译

**英文原标题：** Recombinant factor VIIa versus placebo for spontaneous intracerebral haemorrhage within 2 h of symptom onset (FASTEST): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.

> **英文摘要：**
> BACKGROUND: Recombinant factor VIIa has been shown to slow bleeding in patients with intracerebral haemorrhage (ICH), but no haemostatic agent has been shown to improve clinical outcomes. We aimed to evaluate the safety, clinical efficacy, and effect on growth of ICH and intraventricular haemorrhage (IVH) of recombinant factor VIIa in patients with acute spontaneous ICH who were most likely to benefit from treatment with this agent. METHODS: We conducted a multicentre, prospective, double-blind, randomised, placebo-controlled, adaptive, phase 3 trial (FASTEST) at 93 sites across the USA, Japan, Canada, Spain, Germany, and the UK. Adults aged 18-80 years with a spontaneous ICH of 2-60 mL, IVH in less than two-thirds of one lateral ventricle or in less than a third of both lateral ventricles, a Glasgow Coma Scale score of at least 8, no evidence of recent ischaemic stroke or myocardial infarction, no recent use of anticoagulation medication or other structural cause of ICH, and who had been treated with study medication within 2 h of stroke onset or last known well were eligible for inclusion. Patients were randomly assigned (1:1) by a simple randomisation scheme to either 80 μg/kg recombinant factor VIIa (intervention group) or an identical placebo (placebo group), administered intravenously over 2 min. All investigators and participants were masked to allocated group assignment. The primary outcome was functional outcome at 180 days, measured by modified Rankin Scale (mRS; score 0-2, 3, and 4-6) and analysed by intention to treat in all randomly assigned patients. The primary safety outcome was life-threatening thromboembolic events during the first 4 days, assessed in all randomly assigned participants. The secondary aim was change in ICH volume and ICH plus IVH volume between baseline and 24 h of treatment administration. We performed an ordinal logistic regression, adjusted for age, baseline ICH volume, baseline IVH volume, and pre-stroke mRS. Preplanned interim analyses, including adaptive sample size re-estimation and enrichment to a younger subgroup (aged ≤70 years), were also conducted. This trial is registered with ClinicalTrials.gov (NCT03496883) and is closed to new participants. FINDINGS: Between Dec 3, 2021, and Oct 1, 2025, we screened 3288 patients, of whom 626 participants were randomly assigned and included in the intention-to-treat analyses: 298 (48%) in the placebo group and 328 (52%) in the intervention group. 216 (35%) participants were female and 410 (65%) were male, with a mean age of 61 years (SD 12). Mean time from stroke onset to administration of study drug was 100 min (SD 22). The trial met the prespecified stopping criteria for futility at the second interim analysis. There was no differential effect in the primary clinical outcome measure of mRS at 180 days between the intervention group and placebo group (adjusted common odds ratio 1·09 [95% CI 0·79-1·51]; p=0·61). Life-threatening thromboembolic complications within 4 days occurred in 15 (<5%) participants in the intervention group and in four (1%) in the placebo group (relative risk 3·41 [95% CI 1·14-10·15]; p=0·020). Compared with placebo, recombinant factor VIIa was associated with decreased growth of ICH (-3·7 mL [95% CI -5·4 to -1·9]) and of ICH plus IVH growth (-5·2 mL [-7·6 to -2·8]) between baseline and CT scan at 24 h. INTERPRETATION: Recombinant factor VIIa administered within 2 h of ICH onset slowed haematoma growth, but did not improve functional outcomes and showed a small increased risk of life-threatening thromboembolic complications. Further testing of recombinant factor VIIa in patients with the greatest risk of continued bleeding is ongoing.

> **中文摘要：**
> 背景：重组凝血因子VIIa已被证明可减缓脑出血（ICH）患者的出血速度，但目前尚无止血药物被证明能改善临床结局。本研究旨在评估重组凝血因子VIIa在最可能从该治疗中获益的急性自发性脑出血患者中的安全性、临床疗效以及对脑出血和脑室内出血（IVH）增长的影响。
> 方法：我们在美国、日本、加拿大、西班牙、德国和英国的93个中心开展了一项多中心、前瞻性、双盲、随机、安慰剂对照、自适应的3期试验（FASTEST）。纳入标准为：18-80岁的成人，自发性脑出血量为2-60 mL，脑室内出血受累小于单侧侧脑室的三分之二或双侧侧脑室的三分之一，格拉斯哥昏迷量表评分至少为8分，无近期缺血性卒中或心肌梗死证据，近期未使用抗凝药物或无其他结构性脑出血病因，且在卒中发作或最后已知正常状态后2小时内接受了研究药物治疗。患者通过简单随机化方案按1:1的比例随机分配至80 μg/kg重组凝血因子VIIa组（干预组）或相同的安慰剂组（安慰剂组），在2分钟内完成静脉给药。所有研究者和受试者对分配组别均处于盲态。主要结局是180天时的功能结局，采用改良Rankin量表（mRS；评分0-2、3和4-6）衡量，并对所有随机分配的患者进行意向性治疗分析。主要安全性结局是前4天内发生的危及生命的血栓栓塞事件。次要目标是基线与治疗给药24小时之间脑出血量以及脑出血加脑室内出血总量的变化。我们进行了序数逻辑回归，并根据年龄、基线脑出血量、基线脑室内出血量和病前mRS进行了调整。此外还进行了预设的中期分析，包括自适应样本量重新估计和对年轻亚组（年龄≤70岁）的富集分析。该试验已在ClinicalTrials.gov注册（NCT03496883），现已停止招募。
> 结果：在2021年12月3日至2025年10月1日期间，我们筛选了3288名患者，其中626名受试者被随机分配并纳入意向性治疗分析：安慰剂组298人（48%），干预组328人（52%）。受试者平均年龄为61岁，平均给药时间为发作后100分钟。在第二次中期分析时，该试验达到了预设的无效性终止标准。干预组与安慰剂组在180天mRS主要结局指标上没有差异（调整后的共同优势比 1.09 [95% CI 0.79-1.51]；p=0.61）。4天内危及生命的血栓栓塞并发症在干预组中发生15例（<5%），安慰剂组发生4例（1%）（相对风险 3.41 [95% CI 1.14-10.15]；p=0.020）。与安慰剂相比，重组凝血因子VIIa可显著减少24小时内的脑出血增长（-3.7 mL）和总出血增长（-5.2 mL）。
> 结论：在脑出血发作2小时内给予重组凝血因子VIIa虽能减缓血肿增长，但未能改善功能结局，且会轻微增加危及生命的血栓栓塞风险。目前正在对具有持续出血极高风险的患者进一步测试重组凝血因子VIIa。

### 第二部分 AI 大师评价

FASTEST试验是一项针对超早期（发作2小时内）脑出血治疗的高质量3期RCT。该研究证实了重组凝血因子VIIa在控制血肿扩大方面的生物学效应，但由于其未能转化为180天功能结局的改善，且显著增加了血栓栓塞的安全风险，最终因无效性提前终止。这一结果深刻揭示了在急性脑出血治疗中，单纯的影像学止血获益与患者长期功能恢复之间存在脱节，为未来止血药物的研发和亚组筛选提供了重要的循证依据。

---

## 27. 柳叶刀卵巢癌委员会：迈向以公平为驱动的改革

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41520675)
**期刊：** Lancet (London, England)
**PMID：** 41520675
**DOI：** 10.1016/S0140-6736(25)02463-8

### 第一部分 原文与翻译

**英文原标题：** The Lancet Commission on Ovarian Cancer: towards equity-driven reform.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本报告由《柳叶刀》卵巢癌委员会发布，旨在针对全球范围内卵巢癌诊疗的不平等现状提出系统性的改革方案。委员会通过深入剖析疾病负担、诊疗准入差异以及社会经济影响因素，构建了以公平为核心的全球防治战略路线图。该指南性质的报告强调了打破资源分配壁垒的紧迫性，为各国改善卵巢癌患者预后及制定公共卫生政策提供了权威的学术支撑与行动框架。

---

速递结束，祝您工作愉快！